Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Conditions
Keywords
Autoimmune, Hemolytic, Anemia, Autoimmune Hemolytic Anemia, AIHA, Immune, Thrombocytopenia, Immune Thrombocytopenia, ITP, Blood disorders, Hematology
Brief summary
This is a Phase 2 randomized, dose-blind, multicenter study designed to evaluate the safety, tolerability, efficacy, Pharmacokinetics (PK), and Pharmacodynamics (PD) of treatment with KZR-616 in patients with active Autoimmune Hemolytic Anemia or Immune Thrombocytopenia.
Interventions
DRUGKZR-616
Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
Sponsors
Kezar Life Sciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult patients must be at least 18 years of age at the time of signing informed consent at Screening 2. Body Mass Index (BMI) equal to or greater than 18 kg/m2 3. Have a documented diagnosis of primary or secondary AIHA, ITP, or primary Evans syndrome 4. AIHA or ITP disease activity as follows:: 1. ITP: Per central or local laboratory assessments on 2 separate occasions ≥7 days apart during Screening, a mean Platelet (PLT) ≤30×109/L with no individual PLT \>35×109/L; or for those patients receiving a constant dose of permitted treatments for ITP: a mean PLT \<50×109/L, with no count \>55×109/L 2. AIHA: Hgb ≤10 g/dL and presence of any 2 of the following: i. Haptoglobin \<lower limit of normal (LLN) ii. Corrected reticulocyte count \>upper limit of normal (ULN) iii. LDH \>ULN iv. Indirect bilirubin \>ULN. 5. Documented inadequate response on intolerance to ≥1 standard treatment approach for AIHA or ≥2 standard treatment approaches for ITP
Exclusion criteria
1. Systemic Lupus Erythematosus (SLE) with confirmed anti-phospholipid antibody syndrome, the presence of positive lupus anti-coagulant test, moderate-high titer anti-cardiolipin IgG or IgM or moderate-high titer anti-beta2-globuilin IgG or IgM or severe central nervous system involvement 2. History of clinically significant coagulopathy, hereditary thrombocytopenia, anemia, or family history of thrombocytopenia 3. History of primary immunodeficiency 4. Use of nonpermitted medications within the specified washout periods prior to screening 5. Recent serious or ongoing infection, or risk for serious infection 6. Any of the following laboratory values at Screening: 1. Estimated glomerular filtration rate (eGFR) \<45 ml/min 2. Absolute neutrophil count (ANC) \<1.5×109/L (1500/mm3) 3. Serum aspartate transaminase (AST), serum alanine transaminase (ALT) or serum alkaline phosphatase \>2.5×ULN 4. Thyroid stimulating hormone if outside of the central laboratory normal range and considered clinically significant 5. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) \>1.5×ULN 6. Immunoglobulin G (IgG) \<500 mg/dL 7. For ITP patients only: total bilirubin \>1.5×ULN (3×ULN for patients with documented Gilbert's syndrome). 7. Presence of New York Heart Association Class III or IV heart failure, or uncontrolled blood pressure, or prolonged QT interval 8. Major surgery within 12 weeks before Screening or planned during the study period 9. History of any thrombotic or embolic event within 12 months prior to Screening 10. Clinical evidence of significant unstable or uncontrolled diseases 11. Any active or suspected malignancy or history of documented malignancy within the last 5 years before Screening, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin, or non-muscle invasive bladder cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from Baseline to Week 13 in hematologic parameters of interest in evaluable patients (Hgb for AIHA; Platelets [PLT] for ITP) | 13 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change from Baseline over time in hematologic parameters of interest (Hgb for AIHA; PLT for ITP) | Through study completion, up to 25 weeks | — |
| Proportion of patients with a response at Week 13 | 13 weeks | — |
| Proportion of patients over time with a response | Through study completion, up to 25 weeks | — |
| Time to response | Through study completion, up to 25 weeks | — |
| Proportion of patients over time with loss of response | Through study completion, up to 25 weeks | — |
| Proportion of patients over time with sustained response | Through study completion, up to 25 weeks | — |
| Mean change from Baseline over time in Hct | Through study completion, up to 25 weeks | — |
| Mean change from Baseline over time in Lactate Dehydrogenase (LDH) | Through study completion, up to 25 weeks | — |
| Mean change from Baseline to Week 13 in hematologic parameters of interest (Hgb for AIHA; PLT for ITP) in the intent to treat (ITT) population | 13 weeks | — |
| For AIHA: Proportion of patients with an Hgb >12 g/dL or 2 g/dL higher than Baseline at W13 | 13 weeks | — |
| For AIHA: Number of blood transfusions and units of blood administered over time | Through study completion, up to 25 weeks | — |
| For ITP: Number of platelet transfusions and units of platelets administered over time | Through study completion, up to 25 weeks | — |
| Safety and tolerability of KZR-616 in patients with AIHA or ITP as assessed by monitoring incidence and severity of adverse events (AEs) | Through study completion, up to 25 weeks | — |
| Peak Plasma Concentration (Cmax) following KZR-616 injection | Day 1 | — |
| Time to peak plasma concentration (Tmax) following KZR-616 injection | Day 1 | — |
| Area under the plasma concentration versus time curve (AUC) following KZR-616 injection | Day 1 | — |
| Half-life (T1/2) following KZR-616 injection | Day 1 | — |
| Change from Baseline over time in Patient Global Assessment scores | Baseline and every 4 weeks for 25 weeks | The PtGA is a visual analog scale (VAS) ranging from 0 to 100. Patients will provide a global rating of their disease, for the day of the visit, in response to the statement Considering all the ways that your disease affects you, please rate how you are feeling today by clicking or tapping on the line: using a 100-point VAS where 0 is very good, no symptoms and 100 is very poor, very severe symptoms. |
Countries
Australia, Italy, Poland, Russia, United States
Outcome results
None listed